Vaccine developers Pfizer / BioNTech, together with scientists from the University of Texas, evaluated the effectiveness of a vaccine against the Brazilian strain of coronavirus, New England Journal of Medicine reported.

Experts studied blood samples taken from participants in the last stage of clinical trials of the vaccine, who have already delivered two vaccinations. As it turned out, antibodies capable of neutralizing the new mutation appeared in the blood of these patients.

According to the researchers, the vaccine copes with the Brazilian and British strains in about the same way, but with the South African strains it is slightly worse.